Abstract
Lung cancer is a leading cause of cancer death in many countries. Notch signaling has been demonstrated to frequently participate in the process of lung carcinogenesis. Delta-like ligand 4 (Dll4) is a vascular-specific ligand of Notch, and has a critical role in the angiogenesis of numerous cancers. However, the role of Dll4 in the cross-talk between endothelial cells (ECs) and tumor cells remains obscure. Herein, our study revealed that Dll4-expressing ECs (EC-Dll4) significantly suppressed the proliferation of neighboring non-small cell lung cancer (NSCLC) cells and attenuated the growth of NSCLC xenograft in nude mice. On the contrary, silencing endothelial Dll4 by its specific interference RNA reversed these effects of Dll4 on NSCLC cell proliferation and tumor formation. Furthermore, activation of Notch1, but not Notch2 or Notch3, was enhanced in NSCLC cells cultured with EC-Dll4, as well as in xenografts induced by a mixture of NSCLC cells and EC-Dll4. Interference of Notch1 significantly attenuated Dll4-mediated suppression of NSCLC cell proliferations, indicating that Dll4/Notch1 signaling negatively modulates the NSCLC growth. Moreover, PTEN expression in NSCLC cells was increased by EC-Dll4 or rhDll4 (recombinant human-Dll4 protein), and the induction was impaired by Notch1 interference suggesting that Dll4 could upregulate PTEN expression by Notch1. Taken together, we conclude that the cross-talk between ECs and NSCLC cells by Dll4/Notch1/PTEN signaling pathway inhibits the growth of NSCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Artavanis-Tsakonas S, Rand MD, Lake RJ . (1999). Notch signaling: cell fate control and signal integration in development. Science 284: 770–776.
Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M et al. (2009). The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137: 1124–1135.
Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L et al. (2007). Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res 67: 7954–7959.
Collins BJ, Kleeberger W, Ball DW . (2004). Notch in lung development and lung cancer. Semin Cancer Biol 14: 357–364.
Deftos ML, Bevan MJ . (2000). Notch signaling in T cell development. Curr Opin Immunol 12: 166–172.
Detterbeck FC, Boffa DJ, Tanoue LT . (2009). The new lung cancer staging system. Chest 136: 260–271.
Folkman J . (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186.
Fortini ME . (2009). Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 16: 633–647.
Graziani I, Eliasz S, De Marco MA, Chen Y, Pass HI, De May RM et al. (2008). Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res 68: 9678–9685.
Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A et al. (2005). Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res 65: 3555–3561.
Hofmann JJ, Luisa Iruela-Arispe M . (2007). Notch expression patterns in the retina: an eye on receptor-ligand distribution during angiogenesis. Gene Expr Patterns 7: 461–470.
Indraccolo S, Minuzzo S, Masiero M, Pusceddu I, Persano L, Moserle L et al. (2009). Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res 69: 1314–1323.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. (2008). Cancer Statistics, 2008. CA Cancer J Clin 58: 71–96.
Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP et al. (2007). Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 67: 8051–8057.
Kunnimalaiyaan M, Traeger K, Chen H . (2005). Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 289: G636–G642.
Kunnimalaiyaan M, Chen H . (2007). Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist 12: 535–542.
Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M et al. (2007). Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 67: 11244–11253.
Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD et al. (2007). Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A 104: 3219–3224.
Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D . (2001). Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69: 135–144.
Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP, Brennan K . (2009). Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res 69: 5015–5022.
Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW et al. (2006). Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444: 1032–1037.
Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM et al. (2001). Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 61: 2183–2188.
Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M et al. (2007). Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203–1210.
Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL . (2005). Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65: 8690–8697.
Phng LK, Gerhardt H . (2009). Angiogenesis: a team effort coordinated by notch. Dev Cell 16: 196–208.
Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y et al. (2006). Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083–1087.
Salmena L, Carracedo A, Pandolfi PP . (2008). Tenets of PTEN tumor suppression. Cell 133: 403–414.
Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R et al. (2007). Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109: 4753–4760.
Segarra M, Williams CK, Sierra Mde L, Bernardo M, McCormick PJ, Maric D et al. (2008). Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood 112: 1904–1911.
Wen W, Ding J, Sun W, Wu K, Ning B, Gong W et al. (2010). Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res 70: 2010–2019.
Whelan JT, Forbes SL, Bertrand FE . (2007). CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle 6: 80–84.
Williams CK, Li JL, Murga M, Harris AL, Tosato G . (2006). Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107: 931–939.
Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L et al. (2009). Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 27: 812–826.
Yan M, Plowman GD . (2007). Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res 13: 7243–7246.
Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB et al. (2010). Chronic DLL4 blockade induces vascular neoplasms. Nature 463: E6–E7.
Yin Y, Shen WH . (2008). PTEN: a new guardian of the genome. Oncogene 27: 5443–5453.
Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H et al. (2005). Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8: 13–23.
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (30972965, 31071236 and 30800576) and the Shanghai Pujiang program.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website )
Rights and permissions
About this article
Cite this article
Ding, XY., Ding, J., Wu, K. et al. Cross-talk between endothelial cells and tumor via delta-like ligand4/Notch/PTEN signaling inhibits lung cancer growth. Oncogene 31, 2899–2906 (2012). https://doi.org/10.1038/onc.2011.467
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.467
Keywords
This article is cited by
-
Exosomal microRNA-125a-3p from human adipose-derived mesenchymal stem cells promotes angiogenesis of wound healing through inhibiting PTEN
Molecular and Cellular Biochemistry (2022)
-
The role of Notch ligand, Delta-like ligand 4 (DLL4), in cancer angiogenesis—implications for therapy
European Surgery (2021)
-
Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer
Oncogene (2019)
-
Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumor cells
Clinical & Experimental Metastasis (2019)
-
Engineering a 3D microfluidic culture platform for tumor-treating field application
Scientific Reports (2016)
